Annual CFO
-$134.59 M
-$58.79 M-77.57%
December 1, 2024
Summary
- As of March 13, 2025, FDMT annual cash flow from operations is -$134.59 million, with the most recent change of -$58.79 million (-77.57%) on December 1, 2024.
- During the last 3 years, FDMT annual CFO has fallen by -$65.45 million (-94.67%).
- FDMT annual CFO is now -1733.91% below its all-time high of $8.24 million, reached on December 31, 2017.
Performance
FDMT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$45.86 M
-$16.47 M-56.04%
December 1, 2024
Summary
- As of March 13, 2025, FDMT quarterly cash flow from operations is -$45.86 million, with the most recent change of -$16.47 million (-56.04%) on December 1, 2024.
- Over the past year, FDMT quarterly CFO has dropped by -$15.62 million (-51.65%).
- FDMT quarterly CFO is now -3816.57% below its all-time high of -$1.17 million, reached on September 30, 2023.
Performance
FDMT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$134.59 M
-$21.21 M-18.71%
December 1, 2024
Summary
- As of March 13, 2025, FDMT TTM cash flow from operations is -$134.59 million, with the most recent change of -$21.21 million (-18.71%) on December 1, 2024.
- Over the past year, FDMT TTM CFO has dropped by -$49.43 million (-58.05%).
- FDMT TTM CFO is now -870.33% below its all-time high of -$13.87 million, reached on March 31, 2020.
Performance
FDMT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
FDMT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -77.6% | -51.6% | -58.0% |
| 3 y3 years | -94.7% | -3816.6% | -83.5% |
| 5 y5 years | -266.6% | -3816.6% | -83.5% |
FDMT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -94.7% | at low | -3816.6% | at low | -94.7% | at low |
| 5 y | 5-year | -266.6% | at low | -3816.6% | at low | -870.3% | at low |
| alltime | all time | -1733.9% | at low | -3816.6% | at low | -870.3% | at low |
4D Molecular Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$134.59 M(+77.6%) | -$45.86 M(+56.0%) | -$134.59 M(+18.7%) |
| Sep 2024 | - | -$29.39 M(-2.8%) | -$113.37 M(+33.1%) |
| Jun 2024 | - | -$30.24 M(+4.0%) | -$85.15 M(+10.6%) |
| Mar 2024 | - | -$29.09 M(+18.0%) | -$76.97 M(+1.6%) |
| Dec 2023 | -$75.79 M(-12.6%) | -$24.65 M(+2005.0%) | -$75.79 M(+3.3%) |
| Sep 2023 | - | -$1.17 M(-94.7%) | -$73.36 M(-21.3%) |
| Jun 2023 | - | -$22.07 M(-20.9%) | -$93.20 M(+2.4%) |
| Mar 2023 | - | -$27.91 M(+25.6%) | -$91.04 M(+5.0%) |
| Dec 2022 | -$86.69 M | -$22.21 M(+5.7%) | -$86.69 M(+0.4%) |
| Sep 2022 | - | -$21.02 M(+5.6%) | -$86.31 M(+6.5%) |
| Jun 2022 | - | -$19.90 M(-15.5%) | -$81.01 M(+4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$23.55 M(+7.8%) | -$77.31 M(+11.8%) |
| Dec 2021 | -$69.13 M(+35.8%) | -$21.84 M(+38.9%) | -$69.13 M(+6.7%) |
| Sep 2021 | - | -$15.72 M(-3.0%) | -$64.80 M(+3.8%) |
| Jun 2021 | - | -$16.20 M(+5.4%) | -$62.45 M(+19.1%) |
| Mar 2021 | - | -$15.37 M(-12.2%) | -$52.41 M(+3.0%) |
| Dec 2020 | -$50.91 M(+38.7%) | -$17.50 M(+30.9%) | -$50.91 M(+52.4%) |
| Sep 2020 | - | -$13.37 M(+116.7%) | -$33.41 M(+66.7%) |
| Jun 2020 | - | -$6.17 M(-55.5%) | -$20.04 M(+44.5%) |
| Mar 2020 | - | -$13.87 M | -$13.87 M |
| Dec 2019 | -$36.71 M(+125.9%) | - | - |
| Dec 2018 | -$16.25 M(-297.3%) | - | - |
| Dec 2017 | $8.24 M | - | - |
FAQ
- What is 4D Molecular Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for 4D Molecular Therapeutics?
- What is 4D Molecular Therapeutics annual CFO year-on-year change?
- What is 4D Molecular Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for 4D Molecular Therapeutics?
- What is 4D Molecular Therapeutics quarterly CFO year-on-year change?
- What is 4D Molecular Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for 4D Molecular Therapeutics?
- What is 4D Molecular Therapeutics TTM CFO year-on-year change?
What is 4D Molecular Therapeutics annual cash flow from operations?
The current annual CFO of FDMT is -$134.59 M
What is the all time high annual CFO for 4D Molecular Therapeutics?
4D Molecular Therapeutics all-time high annual cash flow from operations is $8.24 M
What is 4D Molecular Therapeutics annual CFO year-on-year change?
Over the past year, FDMT annual cash flow from operations has changed by -$58.79 M (-77.57%)
What is 4D Molecular Therapeutics quarterly cash flow from operations?
The current quarterly CFO of FDMT is -$45.86 M
What is the all time high quarterly CFO for 4D Molecular Therapeutics?
4D Molecular Therapeutics all-time high quarterly cash flow from operations is -$1.17 M
What is 4D Molecular Therapeutics quarterly CFO year-on-year change?
Over the past year, FDMT quarterly cash flow from operations has changed by -$15.62 M (-51.65%)
What is 4D Molecular Therapeutics TTM cash flow from operations?
The current TTM CFO of FDMT is -$134.59 M
What is the all time high TTM CFO for 4D Molecular Therapeutics?
4D Molecular Therapeutics all-time high TTM cash flow from operations is -$13.87 M
What is 4D Molecular Therapeutics TTM CFO year-on-year change?
Over the past year, FDMT TTM cash flow from operations has changed by -$49.43 M (-58.05%)